Yükleniyor... / Loading...
This study examines the drug erlotinib (Tarceva) used alone or alternating with carboplatin and paclitaxel chemotherapy in patients with EGFR pathway-positive non-small cell lung cancer (NSCLC). It enrolled patients aged 18 and older who had not previously received chemotherapy and had positive EGFR pathway markers. The research was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+3
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age \>= 18 * Histologically or cytologically documented non-small cell lung cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG)performance status (PS)0, 1, 2 * Radiologically measurable or evaluable disease No prior chemotherapy * 1 or 2 epithelial growth factor receptor (EGFR) pathway markers positive at screening * Tumor tissue block or fine needle aspirate Exclusion Criteria: * Any concurrent anticancer therapy or radiation * Other active malignancy * Uncontrolled brain metastases * GI abnormalities * Severe abnormalities of the cornea * Significant cardiac disease * Active infection